Ind-Swift Laboratories Limited (BOM:532305)

Market Cap	16.25B +238.7%
Revenue (ttm)	6.41B +14.2%
Net Income	414.15M -83.5%
EPS	4.84 -86.3%
Shares Out	n/a
PE Ratio	39.23
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	254,583
Open	169.45
Previous Close	168.50
Day's Range	169.45 - 190.00
52-Week Range	87.00 - 187.25
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 28, 2026

About Ind-Swift Laboratories

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson’s disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticance...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1995
• Employees: 1,246
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532305

Financial Performance

In fiscal year 2026, Ind-Swift Laboratories's revenue was 6.41 billion, an increase of 14.17% compared to the previous year's 5.62 billion. Earnings were 414.15 million, a decrease of -83.47%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 19, 2026

Data Sources Report a data error